BNC-210 is a Small Molecule owned by Bionomics, and is involved in 15 clinical trials, of which 14 were completed, and 1 is ongoing.

BNC-210 (IW-2143) is a negative allosteric modulator of alpha-7 nicotinic acetylcholine receptors (alpha7 nAChR). Alpha7 nAChR is a ligand-gated, pentameric ion channel. Alpha7 nAChR is associated with depression, anxiety and also implicated in other important processes that are relevant to depression, such as stress and inflammation. Therefore the drug candidate by allosterically binding to alpha7 nAChR inhibits the actions of acetylcholine there by eliciting anti-depressant and anti-anxiety actions.

The revenue for BNC-210 is expected to reach a total of $520m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BNC-210 NPV Report.

BNC-210 is originated and owned by Bionomics.

BNC-210 Overview

BNC-210 (IW-2143) is under development for the treatment of agitation (anxiety disorder), post-traumatic stress disorder, social anxiety disorder and CCK-4 induced panic disorder. The drug candidate is administered through the oral route. BNC-210 acts by targeting neuronal acetylcholine receptor subunit alpha-7 (CHRNA7). It was also under development for the treatment of depression.

Bionomics Overview

Bionomics, is a biopharmaceutical company that discovers and develops treatments for cancer, and central nervous system disorders such as anxiety, depression and Alzheimer’s disease. The company provides pipeline products such as BNC210, BNC 105, BNC101 and BNC375, among others. It uses various technology platforms including multicore; ionX; and CSC Rx Discovery platform for discovering highly active, functional therapeutic antibodies and small molecule candidates that target cancer stem cells, among others. Bionomics‘ ionX includes systems for high throughput electrophysiology for early and high content evaluation of drug hits. The company conducts clinical studies including post-traumatic stress disorder study, multiple ascending dose study, and generalized anxiety disorder study, dose esclaltion study. Bionomics is headquartered in Thebarton, South Australia, Australia.

The company reported revenues of (Australian Dollars) AUD0.3 million for the fiscal year ended June 2022 (FY2022). The operating loss of the company was AUD22.3 million in FY2022, compared to an operating loss of AUD8.5 million in FY2021. The net loss of the company was AUD21.8 million in FY2022, compared to a net loss of AUD8.7 million in FY2021.

Quick View – BNC-210

Report Segments
  • Innovator
Drug Name
  • BNC-210
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.